<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676686</url>
  </required_header>
  <id_info>
    <org_study_id>Nåva Foot Cream_1</org_study_id>
    <nct_id>NCT03676686</nct_id>
  </id_info>
  <brief_title>Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis</brief_title>
  <official_title>A Prospective Single-arm Investigation to Assess the Efficacy, of Topical &quot;Nåva&quot; Foot Cream for 8 Weeks of Treatment in Patients With Mild to Moderate Tinea Pedis Interdigitalis and Heal Cracks, Calluses and/or Dry Feet.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Natumin Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Natumin Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open post-market clinical investigation that will enroll male and female
      subjects diagnosed with foot fungus and at least one of the following conditions: heal
      cracks, calluses and/or dry feet. The investigation population will consist of 48 subjects
      fulfilling the eligibility criteria for the clinical investigation. The subjects will all be
      treated with the study product, Nåva Foot Cream. The duration of the investigation is
      estimated to 6 months, including a 2-month recruitment period and 2-month follow up period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">November 4, 2019</completion_date>
  <primary_completion_date type="Actual">November 4, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective clinical treatment rate</measure>
    <time_frame>Baseline to end of study (8 weeks)</time_frame>
    <description>Change of total mean score (TMS): Improvement of 8 clinical signs and symptoms of foot fungus calculated as the total score of all using a 4-point severity scale for each symptom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of negative fungal culture</measure>
    <time_frame>Baseline to end of study (8 weeks)</time_frame>
    <description>Frequency of patients with negative fungal culture at end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of negative KOH test</measure>
    <time_frame>Baseline to end of study (8 weeks)</time_frame>
    <description>Frequency of patients with negative KOH test at end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability to the device used</measure>
    <time_frame>Baseline to end of study (8 weeks)</time_frame>
    <description>Tolerability assessed using a 5-point Likert scale (very good, good, moderate, poor, and very poor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical signs and symptoms</measure>
    <time_frame>Baseline to end of study (8 weeks)</time_frame>
    <description>• Long term follow-up (8 weeks) on patient outcomes on heel cracks(rhagades), calluses and/or dry feet (hyperkeratosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Quality of life</measure>
    <time_frame>Baseline to end of study (8 weeks)</time_frame>
    <description>Dermatology QoL Index</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Nåva Foot Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Nåva foot cream administered twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nåva Foot Cream</intervention_name>
    <description>Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.</description>
    <arm_group_label>Nåva Foot Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form

          2. &gt; 18 years of age

          3. Tinea pedis (Athlete's foot) confirmed with positive mycological culture for a
             dermatophyte

          4. Total score of 6-16 when grading the eight sign and symptoms of tinea pedis (erythema,
             erosions, macerations, pruritus, fissures, burning/stinging, hyperkeratosis, odour)
             using a 4-point severity scale (0=absent, 1= mild, 2= moderate, 3=severe)

             o Score of 2 or higher required in at least one of the following: erythema, pruritus,
             macerations or odour

          5. Score of at least 2 (moderate) required in at least one of the following: heel cracks
             (rhagades), calluses and dry feet (hyperkeratosis) using a 5-point severity scale
             (0=absent, 1= mild, 2= moderate, 3= advanced, 4=severe) age

        Exclusion Criteria:

          1. Patients with negative mycological culture

          2. Severe tinea pedis interdigitalis (Athlete's foot) total score of grading sign and
             symptoms &gt; 16

          3. Women pregnant or lactation at time of enrolment

          4. Patients using medicinal topical antifungal therapy within 4 weeks prior to study
             start

          5. Treatment with oral terbinafine, itraconazole or fluconazole within 6 months prior to
             start of study

          6. Treatment with other systemic antifungals within 12 weeks prior to start of study

          7. Treatment with systemic corticosteroids or immunosuppressants within 6 weeks prior to
             start of study

          8. Any other condition that as judged by the investigator may make follow-up or
             investigations inappropriate

          9. Any patient that according to the Declaration of Helsinki is unsuitable for enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Lundvall</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Örebro Län</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carlanderska sjukhuset</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTC</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristetssjukhuset</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

